News

FDA grants priority review to nivolumab for head and neck cancer


 

References

The Food and Drug Administration has granted a priority review for expanded use of nivolumab for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), based on results of Checkmate-141.

CheckMate-141 was stopped early in January 2016 after the study met its primary endpoint of improved overall survival in SCCHN patients receiving nivolumab after platinum-based therapy, compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab).

The FDA is expected to act on the review by Nov. 11, 2016, according to a written statement from Bristol-Myers Squib, makers of nivolumab.

The PD-1 immune checkpoint inhibitor, marketed as Opdivo, was also granted breakthrough therapy designation by the FDA for the treatment of unresectable locally advanced or metastatic urothelial carcinoma that has progressed during or following a platinum-based regimen, according to another written statement from Bristol-Myers Squibb. This is the sixth breakthrough therapy designation for nivolumab.

The breakthrough therapy designation in bladder cancer is based on the results of the phase II CA209-275 trial and other supportive data.

jcraig@frontlinemedcom.com

On Twitter @jessnicolecraig

Recommended Reading

Surgery has edge over surveillance for micropapillary thyroid cancer
MDedge Hematology and Oncology
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
Sentinel node biopsies may be useful in head and neck squamous cell carcinoma
MDedge Hematology and Oncology
Mining for information, participation in clinical trials
MDedge Hematology and Oncology
Accuracy of gene test for thyroid nodules questioned
MDedge Hematology and Oncology
Prognostic significance of HPV status in postoperative squamous-cell carcinoma of the head and neck
MDedge Hematology and Oncology
Resection of recurrence shows survival benefit for adrenocortical carcinoma
MDedge Hematology and Oncology
MyPathway: Targeted therapies show promise in nonindicated tumors
MDedge Hematology and Oncology
Pembrolizumab paired with immunostimulator is safe and tolerable
MDedge Hematology and Oncology
SU2C announces researcher-industry collaboration on immunotherapy
MDedge Hematology and Oncology